CLINICAL STAGE II HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8
Clinical trials for CLINICAL STAGE II HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new CLINICAL STAGE II HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for CLINICAL STAGE II HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can less radiation plus immunotherapy beat standard care for throat cancer?
Disease control OngoingThis study tests whether a lower dose of radiation therapy combined with the immunotherapy drug nivolumab works as well as the standard radiation-plus-chemotherapy approach for people with early-stage HPV-positive throat cancer who have never smoked. About 384 participants will r…
Matched conditions: CLINICAL STAGE II HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 08, 2026 13:12 UTC
-
Can immunotherapy keep HPV throat cancer at bay? major trial seeks answers
Disease control OngoingThis study tests whether adding the immunotherapy drug nivolumab after standard chemo-radiation helps people with HPV-positive throat cancer live longer without their cancer returning. About 636 adults with intermediate-risk, locally advanced disease are being followed. The goal …
Matched conditions: CLINICAL STAGE II HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 03, 2026 12:06 UTC